Terguride but not bromocriptine alleviated glucose tolerance abnormalities and hyperlipidaemia in obese and lean genetically hypertensive Koletsky rats
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
7711008
Knihovny.cz E-zdroje
- MeSH
- bromokriptin farmakologie MeSH
- hyperlipidemie krev MeSH
- hypertenze krev MeSH
- inzulin krev MeSH
- krevní tlak účinky léků MeSH
- krysa rodu Rattus MeSH
- lipidy krev MeSH
- lisurid analogy a deriváty farmakologie MeSH
- modely nemocí na zvířatech MeSH
- obezita krev MeSH
- porucha glukózové tolerance krev MeSH
- potkani inbrední SHR MeSH
- potkani Sprague-Dawley MeSH
- potkani Wistar MeSH
- sexuální faktory MeSH
- tělesná hmotnost účinky léků MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- bromokriptin MeSH
- dironyl MeSH Prohlížeč
- inzulin MeSH
- lipidy MeSH
- lisurid MeSH
Glucose tolerance, total plasma cholesterol and plasma triglycerides were studied in the genetically hypertensive obese Koletsky rats (SHR/N-cp) and in their lean siblings. The initial part of the glucose tolerance curve was substantially elevated in both obese and lean Koletsky animals compared to normotensive Wistar rats. The abnormal glucose tolerance in hypertensive rats was accompanied by increased total plasma cholesterol and plasma triglycerides. Long-term treatment with dopaminergic agonists terguride or bromocriptine (0.2 and 2.0 mg/kg/day, respectively) exerted similar effects on lipid metabolism but both drugs differed in their influence on glucose tolerance. Terguride lowered plasma lipids and normalized glucose tolerance in both obese and lean Koletsky rats. Bromocriptine reduced hyperlipidaemia but did not attenuate the abnormalities of glucose tolerance in either lean or obese Koletsky animals.
